OBJECTIVE: To determine the incidence of breast cancer-related lymphedema (BCRL) during the early survivorship period as well as demographic, lifestyle, and clinical factors associated with BCRL development. DESIGN: The Pathways Study, a prospective cohort study of breast cancer survivors with a mean follow-up time of 20.9 months. SETTING: Kaiser Permanente Northern California medical care program. PARTICIPANTS: We studied 997 women diagnosed from January 9, 2006, through October 15, 2007, with primary invasive breast cancer and who were at least 21 years of age at diagnosis, had no history of any cancer, and spoke English, Spanish, Cantonese, or Mandarin. MAIN OUTCOME MEASURE: Clinical indication for BCRL as determined from outpatient or hospitalization diagnostic codes, outpatient procedural codes, and durable medical equipment orders. RESULTS: A clinical indication for BCRL was found in 133 women (13.3%), with a mean time to diagnosis of 8.3 months (range, 0.7-27.3 months). Being African American (hazard ratio, 1.93; 95% confidence interval, 1.00-3.72) or more educated (P for trend = .03) was associated with an increased risk of BCRL. Removal of at least 1 lymph node (hazard ratio, 1.04; 95% confidence interval, 1.02-1.07) was associated with an increased risk, yet no significant association was observed for type of lymph node surgery. Being obese at breast cancer diagnosis was suggestive of an elevated risk (hazard ratio, 1.43; 95% confidence interval, 0.88-2.31). CONCLUSIONS: In a large cohort study, BCRL occurs among a substantial proportion of early breast cancer survivors. Our findings agree with those of previous studies on the increased risk of BCRL with removal of lymph nodes and being obese, but they point to a differential risk according to race or ethnicity.
OBJECTIVE: To determine the incidence of breast cancer-related lymphedema (BCRL) during the early survivorship period as well as demographic, lifestyle, and clinical factors associated with BCRL development. DESIGN: The Pathways Study, a prospective cohort study of breast cancer survivors with a mean follow-up time of 20.9 months. SETTING: Kaiser Permanente Northern California medical care program. PARTICIPANTS: We studied 997 women diagnosed from January 9, 2006, through October 15, 2007, with primary invasive breast cancer and who were at least 21 years of age at diagnosis, had no history of any cancer, and spoke English, Spanish, Cantonese, or Mandarin. MAIN OUTCOME MEASURE: Clinical indication for BCRL as determined from outpatient or hospitalization diagnostic codes, outpatient procedural codes, and durable medical equipment orders. RESULTS: A clinical indication for BCRL was found in 133 women (13.3%), with a mean time to diagnosis of 8.3 months (range, 0.7-27.3 months). Being African American (hazard ratio, 1.93; 95% confidence interval, 1.00-3.72) or more educated (P for trend = .03) was associated with an increased risk of BCRL. Removal of at least 1 lymph node (hazard ratio, 1.04; 95% confidence interval, 1.02-1.07) was associated with an increased risk, yet no significant association was observed for type of lymph node surgery. Being obese at breast cancer diagnosis was suggestive of an elevated risk (hazard ratio, 1.43; 95% confidence interval, 0.88-2.31). CONCLUSIONS: In a large cohort study, BCRL occurs among a substantial proportion of early breast cancer survivors. Our findings agree with those of previous studies on the increased risk of BCRL with removal of lymph nodes and being obese, but they point to a differential risk according to race or ethnicity.
Authors: Alice B Kornblith; James E Herndon; Raymond B Weiss; Chunfeng Zhang; Enid L Zuckerman; Sylvia Rosenberg; Magriet Mertz; David Payne; Mary Jane Massie; James F Holland; Patti Wingate; Larry Norton; Jimmie C Holland Journal: Cancer Date: 2003-08-15 Impact factor: 6.860
Authors: Andrea L Cheville; Charles L McGarvey; Jeanne A Petrek; Sandra A Russo; Saskia R J Thiadens; Marie E Taylor Journal: Semin Radiat Oncol Date: 2003-07 Impact factor: 5.934
Authors: Kathryn H Schmitz; Marian L Neuhouser; Tanya Agurs-Collins; Krista A Zanetti; Lisa Cadmus-Bertram; Lorraine T Dean; Bettina F Drake Journal: J Natl Cancer Inst Date: 2013-08-29 Impact factor: 13.506
Authors: Justin C Brown; Andrea L Cheville; Julia C Tchou; Susan R Harris; Kathryn H Schmitz Journal: Support Care Cancer Date: 2013-09-07 Impact factor: 3.603
Authors: Gunel Guliyeva; Maria T Huayllani; Daniel Boczar; Francisco R Avila; Xiaona Lu; Antonio Jorge Forte Journal: J Cancer Surviv Date: 2021-01-24 Impact factor: 4.442
Authors: Lauren S Jammallo; Cynthia L Miller; Marybeth Singer; Nora K Horick; Melissa N Skolny; Michelle C Specht; Jean O'Toole; Alphonse G Taghian Journal: Breast Cancer Res Treat Date: 2013-11 Impact factor: 4.872
Authors: Jeanette Ezzo; Eric Manheimer; Margaret L McNeely; Doris M Howell; Robert Weiss; Karin I Johansson; Ting Bao; Linda Bily; Catherine M Tuppo; Anne F Williams; Didem Karadibak Journal: Cochrane Database Syst Rev Date: 2015-05-21
Authors: Heather Greenlee; Danika L Lew; Dawn L Hershman; Vicky A Newman; Lisa Hansen; Sheri J Hartman; Judith Korner; Zaixing Shi; Christine L Sardo Molmenti; Antoine Sayegh; Lou Fehrenbacher; Shelly Lo; Jennifer Klemp; Kristine Rinn; John M Robertson; Joseph Unger; Julie Gralow; Kathy Albain; Robert Krouse; Carol Fabian Journal: Obesity (Silver Spring) Date: 2018-09-11 Impact factor: 5.002
Authors: Mei R Fu; Deborah Axelrod; Amber A Guth; Francis Cartwright; Zeyuan Qiu; Judith D Goldberg; June Kim; Joan Scagliola; Robin Kleinman; Judith Haber Journal: Ann Surg Oncol Date: 2014-05-09 Impact factor: 5.344
Authors: Marilyn L Kwan; Song Yao; Valerie S Lee; Janise M Roh; Qianqian Zhu; Isaac J Ergas; Qian Liu; Yali Zhang; Susan E Kutner; Charles P Quesenberry; Christine B Ambrosone; Lawrence H Kushi Journal: Breast Cancer Res Treat Date: 2016-07-22 Impact factor: 4.872